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Abstract Metformin is quite frequently used off-label in
type 1 diabetes to limit insulin dose requirement.
Guidelines recommend that it can improve glucose con-
trol in those who are overweight and obese but evidence
in support of this is limited. Recently-published findings
from the REducing with MetfOrmin Vascular Adverse
Lesions (REMOVAL) trial suggest that metformin therapy
in type 1 diabetes can reduce atherosclerosis progression,
weight and LDL-cholesterol levels. This provides a new
perspective on metformin therapy in type 1 diabetes and
suggests a potential role for reducing the long-term risk of
cardiovascular disease.
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CIMT Copenhagen Insulin Metformin Therapy
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EDIC Epidemiology of Diabetes Interventions and
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NICE National Institute for Health and Care
Excellence
REMOVAL REducing with MetfOrmin Vascular Adverse
Lesions
UKPDS UK Prospective Diabetes Study
Introduction
Over the last three decades, the Diabetes Control and
Complications Trial (DCCT) and its Epidemiology of
Diabetes Interventions and Complications (EDIC) post-
randomisation follow-up have confirmed that the risk of mi-
crovascular and cardiovascular complications in type 1 diabe-
tes can be reduced with intensive glucose control [1, 2].
However, despite modern insulin formulations administered
by increasingly user-friendly and efficient modes of delivery,
achieving and maintaining target blood glucose levels remains
an elusive goal for many people affected by the condition [3].
One key barrier to achieving target blood glucose control is
the risk and fear of hypoglycaemia. In the DCCT, rates of
severe hypoglycaemia increased exponentially as HbA1c
approached target levels [1]. This problem is becoming more
surmountable, at least for very motivated young individuals
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using continuous subcutaneous insulin delivery [4]. Another
barrier is insulin-induced weight gain leading to insulin resis-
tance and an associated escalating insulin dose requirement,
increasing blood pressure and LDL-cholesterol levels [5].
The concept of adjunct therapy for type 1 diabetes has
emerged in response to these challenges and is based on the
notion that: (1) adding a simple (oral) preparation to insulin
therapy might help to improve glycaemic control; and (2) such
additional therapeutic agents might have effects independent
of glucose lowering to reduce the risk of diabetes complica-
tions. The ideal adjunct therapy would, therefore, reduce in-
sulin dose requirement, lower HbA1c without increasing the
risk of hypoglycaemia, reduce weight, and have direct effects
to reduce the risk of cardiovascular disease and improve life
expectancy [6, 7].
Diabetologists over previous decades have thought that met-
formin might be such a therapy, potentially mirroring its effects
in type 2 diabetes in those with type 1 diabetes. In this review,
we chart the evolution of this idea from small studies in the
1980s up to the recent REducing with MetfOrmin Vascular
Adverse Lesions (REMOVAL) study, the largest trial to date
of metformin in the management of type 1 diabetes [8, 9].
Metformin
As discussed by Sanchez-Rangel and Inzucchi in this issue of
Diabetologia [10], metformin hydrochloride is a simple and
inexpensive biguanide molecule that is currently the first-line
oral glucose-lowering agent in international guidelines for the
management of type 2 diabetes [11, 12]. Its widespread uptake
worldwide was driven by the UK Prospective Diabetes Study
(UKPDS), published in 1998 [13]. Prior to the UKPDS, met-
formin was usually reserved for obese individuals and used
with caution because of its similarity to another biguanide,
phenformin, that was withdrawn from use in 1977 owing to
concerns regarding a potential increased risk of lactic acidosis.
Metformin was not withdrawn in the UK but was unavailable
in the USA between 1977 and 1995. Key findings from the
metformin substudy of the UKPDS were that obese partici-
pants with type 2 diabetes gained less weight than those on
other oral therapies, had lower rates of hypoglycaemia and
had a 33% reduction in the risk of myocardial infarction [13,
14].
Perhaps because of such compelling evidence in type 2
diabetes, off-label use of metformin in type 1 diabetes is quite
common in clinical practice. In a 2016 extract of population
data from Scotland, UK, 15% of adults with type 1 diabetes
had received at least one prescription for metformin and 8%
were using it currently [9]. If practice is similar elsewhere, it is
likely that metformin is currently prescribed for thousands of
people with type 1 diabetes worldwide. In France, in the form
of metformin embonate, it has held a product license for use in
type 1 diabetes since 1996. However, as discussed below,
clinical evidence to guide this practice has been lacking.
Early studies: the 1980s
A small double-blind placebo-controlled crossover trial con-
ducted in France in the mid 1980s reported an improvement in
euglycaemic–hyperinsulinaemic clamp-assessed insulin sen-
sitivity when metformin was added to insulin therapy for
7 days in ten non-obese people with type 1 diabetes [15].
Two years later, in 1987, the late Harry Keen presented an
abstract at the EASD Annual Meeting describing a double-
blind, placebo-controlled crossover trial in eight people with
type 1 diabetes, conducted over 3 weeks, in which no change
in fasting glucose, body weight or insulin dose requirement
was detected with metformin use, despite a significant im-
provement in seven-point capillary glucose profile [16].
Small randomised trials: the 2000s
The early studies described above did not ignite enthusiasm
for research on metformin in type 1 diabetes in the 1990s. It
was more than a decade later, after the publication of the
UKPDS, that a research group from Colorado (USA) present-
ed an abstract at the ADA Meeting in 2000 describing a
double-blind placebo-controlled trial in which 80 adolescent
participants with type 1 diabetes achieved non-sustained im-
provements in HbA1c and weight at 3 months with metformin
use, reverting to baseline by 6 months [17]. The full paper was
not published until 15 years later [18].
In 2002, a group in New Hampshire (USA) reported a
double-blind placebo-controlled trial, in which 62 adults with
type 1 diabetes were randomised to receive metformin or pla-
cebo, showing a reduction in insulin dose requirement without
an improvement in HbA1c when metformin was added to con-
tinuous subcutaneous insulin infusion therapy for 6 months
[19]. The following year (2003), two double-blind placebo-
controlled trials, one carried out in Canada [20] and the other
in Sweden [21], each randomising 30 adolescent individuals
with type 1 diabetes, reported improvements in HbA1c after
3 months of metformin use (by 0.6% [6.6 mmol/mol] and
0.9% [9.9 mmol/mol], respectively); only the Canadian study
demonstrated a significant reduction in insulin dose require-
ment and fasting glucose [20] and neither detected a difference
in weight or in insulin sensitivity [20, 21]. A small study in the
UK, published in 2006, had similar findings to the Canadian
study [22].
Other small non-randomised studies (for example [23])
continued to appear as the decade progressed, but there was
clearly a need for studies in larger groups of individuals if the
field was to move forward. In 2008, Lund et al published a
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double-blind study placebo-controlled trial in which 100 indi-
viduals with type 1 diabetes and suboptimal glycaemic control
were randomised to metformin or placebo for 1 year at the
StenoDiabetes Center (Copenhagen, Denmark). There was no
improvement in HbA1c with metformin, but reductions in in-
sulin dose requirement, weight and LDL-cholesterol (by
5.7 U, 1.74 kg and 0·3 mmol/l, respectively) were observed
[24, 25]. The reduction in LDL-cholesterol did not diminish
following adjustment for a statistically significant imbalance
in concomitant statin use (used in 49% of the metformin group
and 27% of the placebo group) [25]. Around 40% of partici-
pants in both groups reported gastrointestinal adverse effects
during the trial but very few discontinued treatment. The num-
ber of individuals with at least one episode of severe
hypoglycaemia was numerically, but not statistically, higher
with metformin compared with placebo but the rate of severe
hypoglycaemia complicated by coma (n = 6 with metformin;
n = 1 with placebo) approached statistical significance.
Systematic review: 2010
In our systematic review and meta-analysis of these trials
[26], the study by Lund et al [24] contributed more than
half of the 192.8 patient-years available for analysis. We
highlighted the paucity of evidence from only nine small
randomised, double-blind trials, only five of which could
be summarised in a meta-analysis because of heterogene-
ity. We noted a significant reduction in insulin dose re-
quirement (6.6 U/day, p < 0.001) with metformin, and
weight reduction in some trials, but no consistent evi-
dence for HbA1c reduction. We found no information on
cardiovascular outcomes, whether clinical or surrogate
but, in view of the findings by Lund et al, we flagged
LDL-cholesterol as an outcome worthy of further study.
Later that year, the UK National Institute for Health and
Care Excellence (NICE) replicated our meta-analysis and
went on to recommend metformin for adults with type 1 dia-
betes and a BMI ≥25 kg/m2 who ‘want to improve glucose
control while minimising their effective insulin dose’ [27].
The ‘recommendations for research’ included further studies
onmetformin in type 1 diabetes, although outcomes of interest
were not specified.
The ADA followed, stating that ‘adding metformin to in-
sulin therapy may reduce insulin requirements and improve
metabolic control in overweight/obese patients with poorly
controlled type 1 diabetes’ [28]. Given that around 50% of
people with type 1 diabetes are either obese or overweight in
contemporary cohorts [5], and more than 30% have poor
glycaemic control [3], following these recommendations
would have led to a sharp rise in metformin prescribing in
type 1 diabetes.
Lessons from type 2 diabetes?
Types 1 and 2 diabetes are conditions with very different
aetiology and pathogenesis, but many people with long-
duration type 2 diabetes require insulin treatment, and the risk
of cardiovascular disease is high in both conditions. A small
double-blind placebo-controlled crossover trial conducted in
the Netherlands, published in 2000, demonstrated reductions
in HbA1c, weight and insulin dose requirement when metfor-
min was added to treatment for 5 months in insulin-treated
type 2 diabetes [29]. This was followed, in 2009, by the
Hyperinsulinaemia: the Outcome of its Metabolic Effects
(HOME) trial, a double-blind placebo-controlled trial con-
ducted by a different group in the Netherlands. This study
was carried out on a high-risk population with type 2 diabetes
and, thus, had sufficient statistical power to specify clinical
microvascular and cardiovascular outcomes [30]. In 390
insulin-treated individuals with type 2 diabetes studied over
4.3 years, there was a striking 40% reduction in cardiovascular
events, a pre-specified secondary outcome, in those
randomised to metformin. HbA1c, insulin dose requirement
and weight gain were also reduced (by 0.4%, 20 U/day and
3 kg, respectively). That metformin could provide cardiovas-
cular protection in insulin-treated individuals with type 2 dia-
betes provided proof of concept, albeit by extrapolation, for a
similar effect in type 1 diabetes. In terms of mechanism, cho-
lesterol was not lowered but improvements were observed in
several biomarkers of endothelial dysfunction [30, 31].
Larger trials in type 1 diabetes: 2010 to present
The Type 1 Diabetes (T1D) Exchange study On the basis
of supportive data with continuing uncertainty, in 2010
the US type 1 diabetes charity JDRF decided to prioritise
funding for metformin as adjunct therapy in type 1 diabe-
tes. The first of the multicentre trials to emerge (in 2016)
was a double-blind, placebo-controlled randomised clini-
cal trial in 140 overweight and obese adolescent individ-
uals with poor glycaemic control (mean HbA1c, 8.8%
[73 mmol/mol]) and high insulin dose requirements
(mean, 1.1 U/kg) [32]. HbA1c was reduced at 3 months
with metformin (by 0.3% [3.3 mmol/mol]) but this was
not sustained at the end of the 6 month trial (similar find-
ings to those previously reported in 2000 by the Colorado
group [17]). As for other pre-specified outcomes, insulin
dose requirement was reduced by 25% from baseline in
23% of participants taking metformin (compared with 1%
in the placebo group) and BMI was reduced by 10% or
more in 24% of participants taking metformin (compared
with 7% in the placebo group) [33]. No changes were
observed in cholesterol levels. The researchers concluded
that their results did not support prescribing metformin to
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overweight adolescent individuals with type 1 diabetes to
improve glycaemic control and, by implication, did not
support the guideline recommendations, at least in youn-
ger individuals.
The REMOVAL study The REMOVAL study was another
multicentre trial funded by JDRF. Led by one of the current
authors (JRP), it was an international effort that aimed to ad-
dress the lack of cardiovascular data in the area of metformin
use in type 1 diabetes by conducting a double-blind, placebo-
controlled trial to test whether 3 years of metformin treatment
(1000 mg twice daily) added to titrated insulin therapy (to-
wards target HbA1c, 7.0% [53.0 mmol/mol]) reduces progres-
sion of atherosclerosis in adults aged 40 years or older with
confirmed type 1 diabetes and three or more cardiovascular
risk factors [8, 9].
Carotid artery intima-media thickness (cIMT) was selected
as a surrogate outcome for atherosclerotic cardiovascular dis-
ease, since: it predicts cardiovascular events in the general
population [33]; and it was reduced over 6 years of the
EDIC [34] follow-up study in participants with type 1 diabetes
after 6.5 years of intensive glucose control in the DCCT and
this was followed by improved cardiovascular outcomes over
30 years [2]. Prior to REMOVAL, small studies had reported a
reduction of cIMT with metformin use in the metabolic syn-
drome and type 2 diabetes [35, 36]. However, while
REMOVAL was under way, the Carotid Atherosclerosis:
MEtformin for insulin ResistAnce (CAMERA) trial reported












Effect of metformin over 3 years:
clinical interpretation
Primary outcome
Mean cIMT(mm) 0.782 ± 0.162 −0.005 0.166 − No significant reduction in progression
of arteriosclerosis
Secondary outcomes
HbA1c (%) 8.1 ± 0.8 −0.13 0.006 0.016 Reduction at 3 months by 0.24%
(2.6 mmol/mol) (p < 0.0001) but not
sustained thereafter
HbA1c (mmol/mol) 64.0 ± 9.0 −1.4 0.006 0.016
LDL-cholesterol (mmol/l) 2.20 ± 0.71 −0.13 0.012 0.310 Sustained reduction by 0.13 mmol/l
eGFR (ml min−1
[1.73 m]−2)
92.0 ± 21.2 +4.0 <0.0001 0.662 Increased 4 ml min−1 (1.73 m)−2 at 3
months, then declined in parallel with
placebo; requires further investigation
Retinopathy (two-step
change from baseline)
− 0.76 (OR) 0.568 − No effect
Weight (kg) 84.0 ± 14.7 −1.17 <0.0001 0.274 Sustained reduction by 1.17 kg
Insulin dose (U/kg) 0.65 ± 0.28 −0.005 0.545 0.002 After 6 months, reduced by 2 U/day








0.16 1.23 (IRR) 0.442 − No significant change
Treatment satisfaction 31.77 ± 3.94 −0.12 0.668 0.629 No significant change
Maximal common
cIMT(mm)
0.918 ± 0.196 −0.013 0.0093 − Significant reduction in progression of
atherosclerosis
Occurrence of vitamin B12
deficiency (<150 pmol/l)
− 2.76 (HR) 0.0094 − Risk of vitamin B12 deficiency more
than doubled vs placebo
Data were analysed by ANCOVA other than for carotid outcomes (repeated measures regression), retinopathy (logistic regression), hypoglycaemia
(negative binomial regression) and vitamin B12 (Cox proportional hazards)
All analyses were pre-specified unless otherwise stated
a Presented for data analysed by ANCOVA only
AU, arbitrary units; eGFR, estimated GFR; IRR, incidence rate ratio
Diabetologia (2017) 60:1594–1600 1597
no impact of 18 months of metformin treatment on cIMT in
individuals without diabetes but with established coronary
heart disease [37], and the Copenhagen Insulin and
Metformin Therapy (CIMT) trial reported no reduction in
cIMT progression in insulin-treated people with type 2 diabe-
tes [38].
In the REMOVAL study, progression of the primary
outcome, mean far wall cIMT, was not significantly re-
duced with metformin therapy. Mean cIMT is often used
in studies of people without diabetes to reduce variability
as it excludes individual readings of intima-media thick-
ness ≥1.5 mm and plaque (in keeping with the Mannheim
Consensus [39]). However, the tertiary outcome, maximal
far wall cIMT, pre-specified in REMOVAL because of its
use in the DCCT/EDIC study, was reduced by metformin
by twice as much as in the EDIC study over less than half
the period of follow-up, despite more than 80% of partic-
ipants being on statins [9]. Maximal cIMT is a measure of
more advanced stages of atherosclerotic disease, including
focal thickening and plaque [40]. This was an exciting
and positive finding but it is premature to conclude that
the effect of metformin on cIMT in the REMOVAL study
might translate into clinical outcomes, as the contribution
of reduced cIMT progression, per se, to lowered cardio-
vascular disease outcome rates independent of blood glu-
cose levels has not been formally explored in the
DCCT/EDIC.
Along with a change in vascular structure, results of the
REMOVAL study demonstrated a sustained reduction in
weight with metformin (by 1.2 kg), as well as modest re-
ductions in insulin dose requirement (by about 2 U/day from
the 6-month time point onwards) and LDL-cholesterol (by
0.13 mmol/l), despite the high prevalence of statin use [9]
(see Table 1). There was no increase in hypoglycaemia and
no effect of metformin on reactive hyperaemia index, a mea-
sure of small vessel endothelial function. Estimated GFR
was acutely increased upon initiation of metformin (by
4 ml min−1 1.73m−2), an unexpected finding that requires
further investigation, although it is in keeping with some
other recent evidence [41]. Around a quarter of individuals
(twice the rate of those taking placebo) discontinued metfor-
min over 3 years, suggesting that about one in eight had
genuine intolerance with the majority being attributable to
gastrointestinal adverse effects. Biochemical vitamin B12
deficiency was more than doubled over 3 years with metfor-
min use (12%) vs placebo (5%). These findings contribute to
a body of evidence that treatment with metformin reduces
vitamin B12 concentration, suggesting monitoring during
long-term use [28], particularly in type 1 diabetes, in which
there is associated risk of gastroparesis, pernicious anaemia
and coeliac disease.
As in other studies of type 1 diabetes and metformin,
HbA1c was only transiently improved by metformin and
reverted to baseline over the first 6 months of use, probably
as insulin doses were down-titrated by patients in an effort to
avoid hypoglycaemia [9]. The effect of metformin on maxi-
mal cIMT was, therefore, consistent with an anti-
atherosclerotic effect independent of glucose lowering.
Candidate mechanisms include those mediated by activation
of AMP-activated kinase (AMPK) [42], for example, inhibi-
tion of proinflammatory pathways in perivascular adipose tis-
sue [43], inhibition of monocyte-to-macrophage differentia-
tion in vascular tissues [44] or improvement in aspects of
endothelial function [31, 45]. Alternatively, metformin can
inhibit AGE formation by a pathway independent of AMPK
[46]. The contrasting results between the REMOVAL study
and the CAMERA study [37] suggest that an effect of metfor-
min on atherosclerosis progression may be specific to diabe-
tes. In the CIMT trial, as acknowledged by the authors, the
lack of an effect of metformin on cIMT in type 2 diabetes may
have been due to a lack of statistical power [36].
Guidelines for use Guidelines recommend 
metformin for overweight individuals with type 1 
diabetes who wish to improve their glucose control 
and reduce their insulin dose but these recommen-
dations are based on only a few small studies 
Glycaemic control In the recent T1D Exchange 
and REMOVAL trials, reduction in HbA1c with 
metformin in type 1 diabetes was not sustained after 
3 months
LDL-cholesterol and weight In REMOVAL, the 
largest and longest trial of metformin therapy in type 
1 diabetes to date, small but sustained reductions in 
LDL-cholesterol and weight were observed over 3 
years in middle-aged adults 
cIMT These changes observed in REMOVAL were 
accompanied by a reduction in progression of 
maximal cIMT (one of two pre-specified carotid 
outcomes), despite treatment of cholesterol to 
target with statins
Cardiovascular risk REMOVAL suggests that 
metformin has a profile associated with cardiovas-
cular risk reduction rather than sustained glucose-
lowering in type 1 diabetes
Summary of outcomes of metformin use in 
type 1 diabetes
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Summary and conclusions
The recent larger trials provide a new perspective on the use of
metformin in type 1 diabetes. Although there is evidence that
metformin can limit insulin dose requirement, there is little
evidence to support the recommendation by current guidelines
that it can help to improve glucose control in individuals with
type 1 diabetes who are overweight or obese.
Ideally there should be a cardiovascular outcome trial of
metformin in type 1 diabetes but this would involve studying
several thousand individuals over at least 5 years, currently
considered too expensive by the major funding bodies and not
a priority for the pharmaceutical industry. This is a striking
contrast to the situation in type 2 diabetes: no outcome-based
trials of any intervention have been conducted in type 1 dia-
betes to date, with the exception of the DCCT and its EDIC
follow-up study.
Until an outcome-based trial is completed, clinicians and
people with type 1 diabetes will have to decide whether
metformin will be of benefit on the basis of existing evi-
dence. The results of the REMOVAL study suggest that
metformin can reduce weight and LDL-cholesterol and
might reduce atherosclerosis progression, over 3 years in
middle-aged people with long-duration type 1 diabetes al-
ready treated with antihypertensive agents and statins.
These data suggest wider off-label use to improve CVD risk
management in type 1 diabetes.
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